BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
about
Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation CarriersRecurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics.Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent.Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family.Reasons women at elevated risk of breast cancer refuse breast MR imaging screening: ACRIN 6666.Prevalence and Penetrance of BRCA1 and BRCA2 Germline Mutations in Colombian Breast Cancer PatientsPredicting BRCA1 and BRCA2 gene mutation carriers: comparison of LAMBDA, BRCAPRO, Myriad II, and modified Couch models.Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous studyThe BRCAPRO 5.0 model is a useful tool in genetic counseling and clinical management of male breast cancer cases.Characterization of three alternative transcripts of the BRCA1 gene in patients with breast cancer and a family history of breast and/or ovarian cancer who tested negative for pathogenic mutations.Breast and ovarian cancer risk evaluation in families with a disease-causing mutation in BRCA1/2.Evaluation of the BOADICEA risk assessment model in women with a family history of breast cancer.Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort.Risk prediction models for familial breast cancer.Personalized medicine and access to health care: potential for inequitable access?Models of genetic susceptibility to breast cancer.The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.Validity of models for predicting BRCA1 and BRCA2 mutationsUnderestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study.Breast cancer in the young: role of the geneticistEvaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancerPerformance of BRCA1/2 mutation prediction models in Asian Americans.Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United StatesPerformance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family RegistryClinical application of breast cancer risk assessment models.Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications.Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families.Polymorphic variations in the FANCA gene in high-risk non-BRCA1/2 breast cancer individuals from the French Canadian population.Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms.
P2860
Q28085448-E26F2BDC-1B19-4526-9B3A-1A035698184BQ30444706-65D7A885-47CD-4E98-9D3E-46DB20B2C9EFQ33258847-4C87C9B8-A1F0-435D-8EFB-B246BC84DB21Q33327591-48AA9BDE-D43E-42C3-9A09-9278E8D9120CQ33338978-5E900893-A9EF-49AF-832D-8247BA68240EQ33609896-AA23A114-7ADB-41FA-A37A-A5377B9D3A25Q33875862-66A449CE-108B-41D5-8ACA-3E7C122AEFCEQ34102617-8B3F1D0A-9241-490B-AA25-399748D17C12Q34311315-768B7333-AAAD-407D-AACD-7A5B36A4A43EQ34329243-B7B61E0D-20A9-46C0-BF6B-2410F3BFD426Q35167900-CD5F4A54-7632-4066-9192-A42F9EB33615Q35263462-18C6C2B2-3980-411D-B5AE-6C6968F65622Q35815711-B04B308D-DF53-41AE-9716-1DC434C78A77Q35823504-7596E9F4-415F-4975-87C2-6BB320F27E19Q36430753-5DCDA008-79C0-4F3F-9506-6440B6B27AAAQ36543050-D99FD88E-D685-4617-9B62-7870B750C9E7Q36602581-A63E5C64-E135-4027-93AA-AACEF985D008Q36615665-0A92DE0B-D73C-4699-91AA-D3117DE430E8Q36711004-1AB99816-599A-40AF-AE57-CC4D417CFC7EQ36925152-C7E0A546-C880-4FEC-AACA-CEE11D1BC251Q36963403-62700179-BFBE-4BF2-B917-67E4BDB79359Q37004792-91B6F9FA-BCF7-4FD1-91FE-81D40FCB6F14Q37121713-6799813B-F7A9-4F03-8202-6F0E3A6DB3F7Q37155632-25B185B0-64FF-4441-BA70-C152529A114AQ37252756-B5B12386-CF4B-410A-A7AE-CB46F3C2C108Q37707373-086BC9E2-B310-4613-9A5A-33CB6C139D41Q39263736-3D0B58DD-8191-418C-8C87-B7A58C9D24E5Q39395789-CD52E567-0968-4DD8-81CB-CDEADAB23747Q41133980-CDBB6AE9-F110-4F44-A01D-CF207F6D6761Q45870377-37BEE468-AE3A-4527-81D9-F270B4AEED45
P2860
BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
BRCA1 and BRCA2 mutation predi ...... risk French-Canadian families.
@ast
BRCA1 and BRCA2 mutation predi ...... risk French-Canadian families.
@en
BRCA1 and BRCA2 mutation predi ...... risk French-Canadian families.
@nl
type
label
BRCA1 and BRCA2 mutation predi ...... risk French-Canadian families.
@ast
BRCA1 and BRCA2 mutation predi ...... risk French-Canadian families.
@en
BRCA1 and BRCA2 mutation predi ...... risk French-Canadian families.
@nl
prefLabel
BRCA1 and BRCA2 mutation predi ...... risk French-Canadian families.
@ast
BRCA1 and BRCA2 mutation predi ...... risk French-Canadian families.
@en
BRCA1 and BRCA2 mutation predi ...... risk French-Canadian families.
@nl
P2093
P2860
P50
P356
P1476
BRCA1 and BRCA2 mutation predi ...... risk French-Canadian families.
@en
P2093
Francine Durocher
INHERIT BRCAs program members
Paula Smith
P2860
P2888
P356
10.1186/BCR1365
P577
2005-12-12T00:00:00Z
P5875
P6179
1011867769